MDXHEALTH (MDXH.BR)
BE0003844611 - Common Stock
0.342 +0 (+0.88%)
Fundamental Rating
We assign a fundamental rating of 2 out of 10 to MDXH. MDXH was compared to 49 industry peers in the Biotechnology industry. Both the profitability and financial health of MDXH have multiple concerns. While showing a medium growth rate, MDXH is valued expensive at the moment.
Note: MDXH has only limited data available, so a full analysis was not possible, which makes the total rating unfair.
Profitability
Profitability Rating
MDXH has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of MDXH.
VS Industry
Valuation
Valuation Rating
Compared to an average industry price book ratio of 2.62, MDXH is valued rather cheaply
With a price book ratio of 1.07, MDXH is valued correctly.
The Price/Earnings Ratio is negative for MDXH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDXH. No positive earnings are expected for the next year.
VS Industry
Price/Book (1.07) VS Industry: 80% outperformed.
42.63
0.04
Growth
Growth Rating
MDXH shows a strong growth in Revenue. In the last year, the Revenue has grown by 66.62%.
The Revenue is expected to grow by 42.80% on average over the next 5 years. This is a very strong growth
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
MDXH shows a decrease in Revenue. Measured over the last 5 years, the Revenue has been decreasing by -1.77% yearly.
The earnings per share for MDXH have decreased strongly by -16.71% in the last year.
MDXH is expected to show a very negative growth in Earnings Per Share. In the coming 5 years, the EPS will decrease by -112.37% yearly.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -16.71% | -616.57% | -112.37% | N/A | N/A |
| Revenue | -1.77% | 46.5% | 66.62% | 77.51% | 42.8% | N/A | N/A |
Health
Health Rating
A Current Ratio of 1.59 indicates that MDXH should not have too much problems paying its short term obligations.
A Quick Ratio of 1.47 indicates that MDXH should not have too much problems paying its short term obligations.
Compared to an average industry Current Ratio of 2.88, MDXH is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Quick Ratio of 2.88, MDXH is worse placed to pay its short term obligations than its industry peers.
Compared to an average industry Debt to Equity Ratio of 0.12, MDXH is requires more financing than its industry peers. 98% of its industry peers have a better Debt to Equity Ratio.
Based on the Altman-Z score of -3.83, we must say that MDXH is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of MDXH to the average industry Altman-Z score of -0.80, MDXH is less financially healthy than its industry peers.
The Piotroski-F score of MDXH is 3.00. This is a low score and indicates issues in the health and profitability of MDXH.
VS Industry
Debt/Equity (4.08) VS Industry: 2% outperformed.
22.38
0.00
Quick Ratio (1.47) VS Industry: 26% outperformed.
0.34
19.39
Current Ratio (1.59) VS Industry: 26% outperformed.
0.44
19.39
Altman-Z (-3.83) VS Industry: 24% outperformed.
-57.32
65.01
Dividend
Dividend Rating
MDXH does not give a dividend.
MDXHEALTH
EBR:MDXH (5/29/2023, 7:00:00 PM)
0.342
+0 (+0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap9.25M
Analysts88
Price Target1.26 (268.42%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
PT rev (1m)-85.83%
PT rev (3m)-89.14%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)38.13%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.5%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.07 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.67
Fwd EYN/A
FCF(TTM)-1.32
FCFYN/A
OCF(TTM)-1.17
OCFYN/A
SpS1.27
BVpS0.32
TBVpS-2.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM | N/A | ||
| GM | 51.74% |
ROICexgc(3y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc(3y)N/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%
F-Score3
Asset Turnover0.31
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 4.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 84.8% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.47 | ||
| Altman-Z | -3.83 |
F-Score3
WACC6.68%
ROIC/WACCN/A
Cap/Depr(3y)43.48%
Cap/Depr(5y)35.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y-16.71%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-32.03%
EPS Next Y-616.57%
EPS Next 2Y-112.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue growth 1Y66.62%
Revenue growth 3Y46.5%
Revenue growth 5Y-1.77%
Revenue growth Q2Q108.94%
Revenue Next Year77.51%
Revenue Next 2Y42.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-41.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.36%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.31%
OCF growth 3YN/A
OCF growth 5YN/A
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the EuroNext
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the EuroNext
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the EuroNext
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the EuroNext